Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT Post published:March 15, 2022 Post category:Press Release
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Post published:March 14, 2022 Post category:Press Release
Numinus Expands Natural Psychedelic Research with New Biosecurity License Post published:March 14, 2022 Post category:Press Release
Red Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup Post published:March 11, 2022 Post category:Press Release
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets Post published:March 10, 2022 Post category:Press Release
Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange Post published:March 10, 2022 Post category:Press Release
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Post published:March 9, 2022 Post category:Press Release
Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care Post published:March 3, 2022 Post category:Press Release
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Post published:March 2, 2022 Post category:Press Release
Red Light Holland Reports Fiscal Third Quarter Results Post published:March 1, 2022 Post category:Press Release